{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T02:35:14Z","timestamp":1784082914350,"version":"3.55.0"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":3766,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[1999,1]]},"abstract":"<jats:p><jats:bold>Abstract: <\/jats:bold> The effect of interferon alpha (IFN) on myeloproliferation and vascular complications was studied in 32 patients (17 female, 15 male; median age 60.5 yr) with polycythemia vera (PV). IFN therapy was initiated at a median time of 19 months after diagnosis. Ten patients were pretreated with chemotherapy in addition to phlebotomy. IFN dose was 12 megaU\/wk during the first year, 9 megaU\/wk during the second year and 12 megaU\/wk thereafter. During IFN alpha treatment hematocrit level was 45.7% and remained at this level after the second year of treatment, compared to 46.5% before IFN. The frequency of phlebotomy before IFN was 0.49\/month and dropped to 0.19\/month (<jats:italic>p<\/jats:italic>&lt;0.0005) during the first year of IFN treatment. IFN normalized high platelet and leukocyte counts in a majority of patients. The incidence of deep venous thromboses was 3.6%\/yr before IFN alpha and 1.8%\/yr during the first year of treatment. IFN\u2010induced side\u2010effects were mainly flu\u2010like symptoms, fever, fatigue and arthralgia. In conclusion, IFN allowed the reduction of the dose of chemotherapy and decreased the need of phlebotomy. Despite improvement of hematological parameters, it is still uncertain whether IFN alpha can improve clinical symptoms in PV.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1999.tb01110.x","type":"journal-article","created":{"date-parts":[[2010,7,18]],"date-time":"2010-07-18T10:48:25Z","timestamp":1279450105000},"page":"27-31","source":"Crossref","is-referenced-by-count":26,"title":["The effect of interferon alpha on myeloproliferation and vascular complications in polycythemia vera"],"prefix":"10.1111","volume":"62","author":[{"given":"N.","family":"Heis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rintelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kn\u00f6bl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Gisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"172","article-title":"Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera","volume":"23","author":"Tartaglia AP","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V90.9.3370","article-title":"Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years","volume":"9","author":"Najean Y.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830340108"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198604243141701"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V76.4.664.664","article-title":"A new treatment for polycythemia vera: recombinant interferon alfa","volume":"76","author":"Silver RT","year":"1990","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V77.12.2790.2790"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830440303"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-11-199312010-00006"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01737425"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830480112"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.00303.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830430419"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1995.tb03306.x"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92142-9"},{"key":"e_1_2_1_16_2","first-page":"132","article-title":"Therapeutic recommendations in polycythemia vera based on polycythemia vera study group protocols","volume":"23","author":"Berk PD","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199157"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830170402"},{"key":"e_1_2_1_19_2","first-page":"30","article-title":"Influence of therapy on causes of death in polycythemia vera","volume":"44","author":"Wasserman LR","year":"1981","journal-title":"Trans Assoc Am Physicians"},{"key":"e_1_2_1_20_2","first-page":"40","article-title":"Interferon alpha: effects of long term treatment for polycythaemia vera","volume":"34","author":"Silver RT","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074372"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1999.tb01110.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1999.tb01110.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T18:19:42Z","timestamp":1698603582000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1999.tb01110.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1999,1]]}},"alternative-id":["10.1111\/j.1600-0609.1999.tb01110.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1999.tb01110.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,1]]}}}